Sort   by:  
 Page size 
UnknownODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Not available
S-EPMC7809782 | biostudies-literature
UnknownOnce-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Not available
S-EPMC12509724 | biostudies-literature
UnknownDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Not available
S-EPMC9630157 | biostudies-literature
UnknownChildren living with HIV in Europe: do migrants have worse treatment outcomes?
Not available
S-EPMC9293243 | biostudies-literature
UnknownDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Not available
S-EPMC7614690 | biostudies-literature
UnknownOnce-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Not available
S-EPMC9646993 | biostudies-literature
UnknownNeuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Not available
S-EPMC7616346 | biostudies-literature
UnknownImmunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials.
Not available
S-EPMC10867612 | biostudies-literature
Sort   by:  
 Page size